^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib

Excerpt:
Clinically, in an open-label phase II trial, infigratinib demonstrated a confirmed overall response rate (cORR) of 39.3% in FGFR2 fusion-positive cholangiocarcinoma patients who received infigratinib as second-line therapy (Figure 7). Additionally, clinical benefit was observed in...solid tumors tested positive for FGFR fusions.
DOI:
10.1200/PO.19.00365